TP53 and cancer: Accordingly, in this study we found that the treatment with AG490 JAK2/STAT3 inhibitor reduced cell survival in glioblastoma (U373) and pancreatic (Panc1) cancer cell lines, harboring R273 hot spot mutation in DNA binding domain of p53 (Figures 1A,B).